5-(4-methylpiperazin-1-yl)-3-propyl-2-(1H-pyrrolo[2,3-b]pyridin-3-yl)-3H-imidazo[4,5-b]pyridine

ID: ALA2326404

Chembl Id: CHEMBL2326404

PubChem CID: 136238985

Max Phase: Preclinical

Molecular Formula: C21H25N7

Molecular Weight: 375.48

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CCCn1c(-c2c[nH]c3ncccc23)nc2ccc(N3CCN(C)CC3)nc21

Standard InChI:  InChI=1S/C21H25N7/c1-3-9-28-20(16-14-23-19-15(16)5-4-8-22-19)24-17-6-7-18(25-21(17)28)27-12-10-26(2)11-13-27/h4-8,14H,3,9-13H2,1-2H3,(H,22,23)

Standard InChI Key:  KLZORIPFVDETRC-UHFFFAOYSA-N

Alternative Forms

  1. Alternative Forms:

    ALA2326404

    ---
  2. Parent:

    ALA2326404

    ---

Associated Targets(non-human)

RAW264.7 (28094 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mus musculus (284745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Tlr4 Toll-like receptor 4/Ly96 (54 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 375.48Molecular Weight (Monoisotopic): 375.2171AlogP: 3.14#Rotatable Bonds: 4
Polar Surface Area: 65.87Molecular Species: NEUTRALHBA: 6HBD: 1
#RO5 Violations: HBA (Lipinski): 7HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: 13.91CX Basic pKa: 7.68CX LogP: 3.34CX LogD: 2.88
Aromatic Rings: 4Heavy Atoms: 28QED Weighted: 0.59Np Likeness Score: -1.63

References

1. Chen G, Liu Z, Zhang Y, Shan X, Jiang L, Zhao Y, He W, Feng Z, Yang S, Liang G..  (2013)  Synthesis and Anti-inflammatory Evaluation of Novel Benzimidazole and Imidazopyridine Derivatives.,  (1): [PMID:24900565] [10.1021/ml300282t]
2. Liu Z, Tang L, Zhu H, Xu T, Qiu C, Zheng S, Gu Y, Feng J, Zhang Y, Liang G..  (2016)  Design, Synthesis, and Structure-Activity Relationship Study of Novel Indole-2-carboxamide Derivatives as Anti-inflammatory Agents for the Treatment of Sepsis.,  59  (10): [PMID:27142640] [10.1021/acs.jmedchem.5b02006]
3. Liu Z, Chen L, Yu P, Zhang Y, Fang B, Wu C, Luo W, Chen X, Li C, Liang G..  (2019)  Discovery of 3-(Indol-5-yl)-indazole Derivatives as Novel Myeloid Differentiation Protein 2/Toll-like Receptor 4 Antagonists for Treatment of Acute Lung Injury.,  62  (11): [PMID:30998353] [10.1021/acs.jmedchem.9b00316]

Source